50th week of 2011 patent applcation highlights part 40 |
Patent application number | Title | Published |
20110306589 | NITROGEN CONTAINING HETEROARYL COMPOUNDS - The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) | 2011-12-15 |
20110306590 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS - Aryl- and heteroaryl-nitrogen heterocyclic compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like. | 2011-12-15 |
20110306591 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS - Heteroaryloxycarbocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like. | 2011-12-15 |
20110306592 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I). | 2011-12-15 |
20110306593 | GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more disease associated with the central nervous system using such compounds or pharmaceutical compostions. | 2011-12-15 |
20110306594 | 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION UTILIZING THE SAME - Provided are novel compound that is useful as a treatment agent or a prophylactic agent for cardiac failure, cardiac failure due to dystelectasis, left ventricular diastolic impairment, angina or cardiac infarct, hypertension, ischemic cardiac disease, and myocardial relaxation impairment recognized in cardiac failure, atrial fibrillation or ventricular arrhythmia, and a pharmaceutical composition containing the same. The invention pertains to a 1,4-benzothiazepine-1-oxide derivative represented by general formula [I] (In the formula, R represents a hydrogen atom or a hydroxyl group.) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same [I]. | 2011-12-15 |
20110306595 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. | 2011-12-15 |
20110306596 | BENZAZEPINE INHIBITORS OF GAMMA-SECRETASE - The present invention relates to new benzazepine inhibitors of gamma-secretase activity, pharmaceutical compositions thereof, and methods of use thereof. | 2011-12-15 |
20110306597 | Nicotinamide Derivatives - The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions. | 2011-12-15 |
20110306598 | Use of the association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor in the treatment of heart failure - Use of the association of a selective and specific sinus node I | 2011-12-15 |
20110306599 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF - Provided is an agent for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like. | 2011-12-15 |
20110306600 | NOVEL THERAPEUTIC COMPOUNDS - The invention discloses a number of therapeutic compounds and a method of treating a disorder in mammal. | 2011-12-15 |
20110306601 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION - Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists, to enhance brain neurotrophism. | 2011-12-15 |
20110306602 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES - The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. | 2011-12-15 |
20110306604 | 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS - Compounds of Formula (I): (where variables R | 2011-12-15 |
20110306605 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER - Compounds including those of the Formula I | 2011-12-15 |
20110306606 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME - The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyridine derivative compound of the present invention increases osteoblast activity and effectively inhibits the differentiation of osteoclasts, and thus can be usefully used for the prevention and treatment of osteoporosis. | 2011-12-15 |
20110306607 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS - The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2011-12-15 |
20110306608 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE AND INFLAMMATORY DISEASES - The disclosure provides methods and compositions for the treatment of vascular, autoimmune and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor. | 2011-12-15 |
20110306609 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS - Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2011-12-15 |
20110306610 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND - The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): | 2011-12-15 |
20110306611 | Transcription factor modulating compounds and methods of use thereof - Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms. | 2011-12-15 |
20110306612 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS - Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2011-12-15 |
20110306613 | CHEMICAL COMPOUNDS - There is provided pyrimidinyl compounds of Formula (I), | 2011-12-15 |
20110306614 | N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors - The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives. | 2011-12-15 |
20110306615 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF - According to the present invention, a compound represented by formula (I): | 2011-12-15 |
20110306616 | Novel Compounds as Cannabinoid Receptor Ligands - Disclosed herein are cannabinoid receptor ligands of formula (I) | 2011-12-15 |
20110306617 | Methods and Compositions for the Production of High Concentration Alloxazine Solutions - Methods are provided for preparation of compositions having an enhanced level of soluble alloxazine, as compared to compositions prepared using conventional techniques. Compositions and a riboflavin form having higher solubility in solution is also provided. | 2011-12-15 |
20110306618 | JNK Modulators - Compounds of formula (I) modulate JNK wherein X | 2011-12-15 |
20110306619 | 6-PHENYL-2-[((PIPERIDIN-4-YLMETHYL)-PIPERAZIN-1YL) OR PIPERAZIN 1-YLMETHYL)-PIPERIDIN-1-YL)]-IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES AND THEIR USE - Provided are heterocyclic compounds, their synthesis and pharmaceutical compositions including them for the treatment of disorders, in particular, cancer. | 2011-12-15 |
20110306620 | Heteroarylpiperidine And-Piperazine Derivatives - Heteroarylpiperidine and -piperazine derivatives of the formula (I), | 2011-12-15 |
20110306621 | ACYLGUANIDINE DERIVATIVES - An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on a serotonin 5-HT | 2011-12-15 |
20110306622 | METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED SUBJECTS - This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds. | 2011-12-15 |
20110306623 | NOVEL COMPOUNDS COMPRISING A 3-(5-ALKOXYPYRIMIDIN-2-YL) PYRIMIDIN-4(3H)-ONE STRUCTURE AND DRUGS THAT COMPRISE SAME - Provided are novel compounds that have both angiotensin II receptor-antagonist effects and PPAR-activating effects that are useful as agents for preventing and/or treating hypertension, heart disease, angina, cerebral vascular accident, cerebrovascular disorder, ischemic peripheral circulatory disorder, kidney disease, atherosclerosis, inflammatory disease, type 2 diabetes mellitus, diabetic complication, insulin resistance syndrome, Syndrome X, metabolic syndrome, and hyperinsulinemia. Disclosed are 3-(5-alkoxypyrimidin-2-yl)pyrimidin-4(3H)-one derivatives represented by the General formula (I): [wherein R represents a C | 2011-12-15 |
20110306624 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 2011-12-15 |
20110306625 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. | 2011-12-15 |
20110306626 | IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS - The present invention is directed to imidazolinone derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 2011-12-15 |
20110306627 | Morphinan Compounds - This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ | 2011-12-15 |
20110306629 | NOVEL C-1 ANALOGS OF PANCRATISTATIN AND 7-DEOXYPANCRATISTATIN AND PROCESSES FOR THEIR PREPARATION - The present application relates to novel C-1 substituted analogues of pancratistatin and 7-dexoypancratistatin of Formula (I), pharmaceutical compositions thereof and the use of said compounds of Formula (I) in the treatment of cancer The application also relates to processes for the preparation of said compound of Formula (I) and intermediates thereof. | 2011-12-15 |
20110306630 | PHARMACEUTICAL COMPOSITIONS COMPRISING COLLOIDAL SILICON DIOXIDE - A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight. | 2011-12-15 |
20110306631 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER - The present invention relates to a new family of triple substituted phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition or cancer, their use as a medicament, especially for treating a neurodegenerative or haematological disease or condition or cancer, and a pharmaceutical composition comprising the compounds. | 2011-12-15 |
20110306632 | Solid Dispersions Containing Kinase Inhibitors - A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer. | 2011-12-15 |
20110306633 | SELECTIVE M4 RECEPTOR ANTAGONIST AND ITS MEDICAL USE - The present invention provides a selective M4 receptor antagonist, levorotatory demethylated phencynonate or its nontoxic pharmaceutically acceptable salt, a pharmaceutical composition comprising this compound, and a use thereof in the manufacture of a medicament for the treatment of motion dysfunction, such as, tremor, rigor and the like caused by Parkinson's disease (PD). The structure, of the compound is shown in Formula IIa: | 2011-12-15 |
20110306634 | Amorphous Salt of a Macrocyclic Inhibitor of HCV - The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula: | 2011-12-15 |
20110306635 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS - The invention relates specifically to the use of certain 4-[1-(1H-Imidazol-4-yl)-ethyl]-2,3-substituted pyridine compounds and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation. | 2011-12-15 |
20110306636 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS - The present invention provides oxadiazole pyridine derivatives of Formula (I), their use as medicaments and their use for treating multiple sclerosis and other diseases. | 2011-12-15 |
20110306637 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2011-12-15 |
20110306638 | BENZISOXAZOLE PIPERIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE DERIVATIVES AND THEIR USE - The invention relates to a benzisoxazolyl piperidine derivative having the following general formula, a salt or a hydrate thereof, | 2011-12-15 |
20110306639 | HYDROCARBYLIDENE NITROHYDROZINECARBOXIMIDAMIDES AND A METHOD FOR MAKING THE SAME, AS WELL AS THEIR USES AS AN INSECTICIDE - The present invention discloses hydrocarbylidene nitrohydrozinecarboximidamides and the use thereof as well as a method for making the same. The structural general formula of the compounds are shown in formula I, wherein, R1 is C1-C10 saturated and/or unsaturated aliphatic hydrocarbonyl, benzyl, substituted benzyl, halogenated picolyl, halogenated thiazolyl methyl, tetrahydrofuryl methyl or oxazolyl methyl; R2 is hydrogen, C1-C5 saturated and/or unsaturated aliphatic hydrocarbonyl, phenyl, substituted phenyl, pyridyl or substituted pyridyl; R3 is hydrogen, C1-C10 saturated and/or unsaturated aliphatic hydrocarbonyl, furyl, phenyl, substituted phenyl, benzyl or substituted benzyl. The tests of insecticidal activity show that the hydrocarbylidene nitrohydrozinecarboximidamides shown by formula (I) have high preventive efficiency against insect pests of plants, such as aphid, plant hopper, cotton bollworm, asparagus caterpillar, and the like, and can be used as plant insecticides. | 2011-12-15 |
20110306640 | DABIGATRAN IN TUMOUR THERAPY - The invention relates to the use of dabigatran etexilate of Formula (I) optionally in the form of the pharmaceutically acceptable salts thereof, as well as new medicament formulations for the treatment of tumours. | 2011-12-15 |
20110306641 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL PREPARATION INCLUDING SAME - The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing same, a pharmaceutical composition for prevention and treatment of osteoporosis including same, applications of same for preparing the therapeutic agent of osteoporosis prevention and treatment, and a method for prevention and treatment of osteoporosis using same. The 2,6-substituted-3-nitropyridine derivative compound of the present invention effectively increases osteoblast activity and also inhibits the formation of osteoclasts, so that it may be usefully used for the prevention and treatment of osteoporosis. | 2011-12-15 |
20110306642 | 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved. | 2011-12-15 |
20110306643 | TRIGLYCERIDE-CONTAINING DORMANCY SPRAYS - There is described a suspension concentrate, containing the following components:
| 2011-12-15 |
20110306644 | METALLOENZYME INHIBITOR COMPOUNDS - The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. | 2011-12-15 |
20110306645 | Novel ortho-substituted arylamide derivatives - The present invention relates to novel ortho-substituted arylamide derivatives of the general formula (I) | 2011-12-15 |
20110306646 | FUNGICIDAL N-(PHENYLCYCLOALKYL)CARBOXAMIDE, N-(BENZYLCYCLOALKYL)CARBOXAMIDE AND THIOCARBOXAMIDE DERIVATIVES - The present invention relates to a N-(Phenylcycloalkyl)carboxamide or N-(Benzylcycloalkyl)carboxamide or its thiocarboxamide derivative of formula (I) wherein A represents a carbo-linked, unsaturated or partially saturated, substituted or non-substituted 5-membered heterocyclyl group, T represents an oxygen or a sulphur atom, B represents a non aromatic carbocycle that can be substituted by one to four C | 2011-12-15 |
20110306647 | NOVEL POLYMORPHS OF SUNITINIB MALATE - The present invention provides a novel crystalline form of sunitinib malate, process for its preparation and to pharmaceutical composition containing it. The present invention also provides a process for preparation of sunitinib malate crystal form I. Thus, for example, sunitinib malate was added to water, the mixture was heated to 80 deg C. to obtain a clear solution and stirred for 30 minutes at 80 deg C., slowly cooled to room temperature and the solution was subjected to freeze drying at about −90 deg C. for 8 hours to give sunitinib malate crystalline form III. | 2011-12-15 |
20110306648 | APOPTOSIS INHIBITOR - Disclosed is an apoptosis inhibitor containing an indole derivative represented by the following formula (1) or a salt thereof as an active ingredient, wherein R | 2011-12-15 |
20110306649 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Prodrugs of ion channeling modulating compounds, including, for example, prodrugs of the ion channel modulating compound of the following formula: | 2011-12-15 |
20110306650 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE - The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications. | 2011-12-15 |
20110306651 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a | 2011-12-15 |
20110306652 | COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN - Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. | 2011-12-15 |
20110306653 | STABILIZATION METHOD OF FUNCTIONAL NUCLEIC ACID - This invention is intended to enhance and improve the resistance of a single- or double-stranded nucleic acid fragment comprising a base sequence of a functional nucleic acid to degradation by nucleolytic enzymes in a simple and cost-effective manner. The single- or double-stranded nucleic acid fragment comprises, ligated to at least one end thereof, hairpin-shaped DNA comprising: (A) a nucleic acid region comprising 2 to 5 arbitrary nucleotides; (B) a nucleic acid region comprising a “gna” or “gnna” base sequence, wherein each “n” represents “g”, “t”, “a”, or “c”, a base analogue, or a modified base; and (C) a nucleic acid region comprising a base sequence complementary to the nucleic acid region (A), sequentially from the 5′ end toward the 3′ end. | 2011-12-15 |
20110306654 | Methods for identifying analgesic agents - The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders. | 2011-12-15 |
20110306655 | METHODS FOR IDENTIFYING AND COMPOUNDS USEFUL FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING INFLAMMATION - The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the inhibition of the maturation of dendritic cells. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by maturation of dendritic cells including infections, allograft reactions, inflammation, allergic and autoimmune diseases, and cancer. | 2011-12-15 |
20110306656 | Biologically tolerated low molecular weight polyethylenimines - The invention relates to low molecular weight polyethylenimines, to vectors for inserting nucleic acids into cells which contain low molecular weight polyethylenimines, and to the preparation and use of the low molecular weight polyethylenimine and the vector. | 2011-12-15 |
20110306657 | POLYALKYLENEIMINE-GRAFT-BIODEGRADABLE POLYMERS FOR DELIVERY OF BIOACTIVE AGENTS - The invention provides poly(alkyleneimine)-graft-biodegradable polymers and methods for preparing such polymers. The poly(alkyleneimine)-graft-chitosan polymers may optionally contain a targeting element. The poly(alkyleneimine)-graft polymers may be used to deliver a bioactive agent into a cell. | 2011-12-15 |
20110306658 | Novel compound obtained from gamboge resin, and medical uses of the same - Disclosed herein are seventeen new compounds obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds have activities in inhibiting the growth of tumor/cancer cells. | 2011-12-15 |
20110306659 | OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION - Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine. | 2011-12-15 |
20110306660 | LIQUID CANNABINOID FORMULATIONS - Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. | 2011-12-15 |
20110306661 | HYDROGEL CONTACT LENS FOR SUSTAINED DRUG RELEASE AND DRUG RELEASE METHOD USING HYDROGEL CONTACT LENS FOR SUSTAINED DRUG RELEASE - Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer. | 2011-12-15 |
20110306662 | Steroid-Derived Cyclopamine Analogs and Methods for Using the Same in the Prevention or Treatment of Cancer - The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided. | 2011-12-15 |
20110306663 | TRIHEPTANOIN DIET FOR ADULT POLYGLUCOSAN BODY DISEASE (APBD) TREATMENT - Compositions and methods for the treatment and management of adult polyglucosan body disease (APBD) are disclosed herein. The APBD patients studied in the present invention experienced stabilization of disease progression and limited functional improvement with dietary triheptanoin (C7TG). The amount of C7TG administered to the patient daily for 6-8 months was 1-2 g/kg/24 hrs. The present invention demonstrates, for the first time, the arrest of clinical deterioration with limited functional recovery in APBD with triheptanoin diet therapy. | 2011-12-15 |
20110306664 | MEDICAL DIETARY COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASES - Medical dietary composition for treating neurodegenerative diseases such as Alzheimer, Parkinson's disease, and more preferably adrenoleukodystrophy comprising a mixture of glyceryl trioleate (GTO), glyceryl trierucate (GTE) and at least one conjugated linoleic acid as active ingredient, in combination with suitable excipients and/or diluents. | 2011-12-15 |
20110306665 | COSMETIC PREPARATION, METHOD FOR PRODUCING SAME, COMPOSITION FOR COSMETIC PREPARATIONS, COSMETIC PREPARATION CONTAINING THE COMPOSITION FOR COSMETIC PREPARATIONS AND METHOD FOR PRODUCING SAME, AND CLEANSER FOR INDUSTRIAL USE - The present invention is related to: (1) a cosmetic preparation including an emulsifying agent, 1,3-propanediol (PDO), and a PDO difatty acid ester, wherein the fatty acids constituting the PDO difatty acid ester are one or two or more types of fatty acids selected from isostearic acid, n-octanoic acid, and n-decanoic acid, and a method for producing the cosmetic preparation; (2) a composition for cosmetic preparations, which includes the PDO difatty acid ester, a cosmetic preparation including the composition for cosmetic preparations, and a method for producing the cosmetic preparation; and (3) a cleanser for industrial use, which includes a PDO difatty acid ester that has fatty acid residues of n-octanoic acid and n-decanoic acid. The present invention is able to provide: a cosmetic preparation, a composition for cosmetic preparations, and a cosmetic preparation including the composition for cosmetic preparations, which have excellent cleansing properties, low irritation properties, moisturizing properties, and feeling of use, with reduced load on the environment; methods for producing the same; and, in addition, a cleanser for industrial use which has excellent cleansing properties and low corrosion properties, with reduced load on the environment. | 2011-12-15 |
20110306666 | NEW PLANT DERIVED SEED EXTRACT RICH IN ESSENTIALLY FATTY ACIDS DERIVED FROM SALVIA HISPANICA L. SEED: COMPOSITION OF MATTER, MANUFACTURING PROCESS AND USE | 2011-12-15 |
20110306667 | Stabilization Of Perhydrolases - Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided. | 2011-12-15 |
20110306668 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID - A process for synthesizing and screening solution phase derived libraries of fenbufen and ethacrynic acid is provided in the present invention. Compounds in the present invention having cytotoxicities are useful for a variety of therapeutic applications. | 2011-12-15 |
20110306669 | RAPID ONSET AND SHORT TERM MODAFINIL COMPOSITIONS AND METHODS OF USE THEREOF - Compositions are described that comprise a modafÊnil component that is a combination of the d- and l-enantiomers of modafinil and wherein the modafÊnil component is greater than 50% by weight d-modafÊnil for use in promoting or enhancing the state of wakefulness, alertness, and/or central nervous system stimulation in an individual. | 2011-12-15 |
20110306670 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM - Pentafluorosulfanylbenzoylguanidines of the formula I and II | 2011-12-15 |
20110306671 | AMIDE DERIVATIVES OF ETHACRYNIC ACID - The invention provides ethacrynic acid derivatives useful to prevent, inhibit or treat a variety of disorders or diseases including cancer and inflammatory disorders. | 2011-12-15 |
20110306672 | CERAMIDE-ANALOGOUS METABOLITES - This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis. | 2011-12-15 |
20110306673 | CRYSTALLINE FORMS OF (1RS,2RS,6RS)-6-DIMETHYLAMINOMETHYL-1-(3-METHOXYPHENYL)CYCLOHEXANE-1,3-DI- OL HYDROCHLORIDE - This invention relates to solid crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1. | 2011-12-15 |
20110306674 | Pharmaceutical Combination - A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration. | 2011-12-15 |
20110306675 | COMPOSITIONS AND METHODS FOR INHIBITING NF-KB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS - Disclosed are compositions and methods for inhibiting NF-κB mediated cellular proliferation and metastasis. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2011-12-15 |
20110306676 | Method and Medicament for Pain Management - The present invention relates to a method and an apparatus for treating pain in a patient, such as a veterinary patient. The method comprises the step of administering an inhalation anaesthetic at sub-anaesthetic levels to the patient during an anaesthesia of the patient. A suitable agent may be methoxyflurane. | 2011-12-15 |
20110306677 | Pressure Sensitive Adhesive Composition and Pressure Sensitive Adhesive Tape - A pressure sensitive adhesive composition comprising, as a rubber component solid at ordinary temperature, from 10% by mass or more to less than 50% by mass of polyisoprene, from more than 50% by mass to 90% by mass or less of a styrene-isoprene-styrene block copolymer and 0 to 30% by mass of polyisobutylene, and further comprising, per 100 parts by mass of the solid rubber component, 1 to 30 parts by mass of polyisobutylene liquid at ordinary temperature, 50 to 120 parts by mass of a tackifier, and 1 to 40 parts by mass of a plasticizer liquid at ordinary temperature; and a pressure sensitive adhesive tape comprising a base material and the above-described pressure sensitive adhesive composition provided on the base material. | 2011-12-15 |
20110306678 | Angle-dependent Interference Pigments - An angle-dependent interference pigment based on transparent or translucent inorganic flake serving as a substrate is provided. The substrate is coated by coatings (A)+(B)+(C) and optionally coating (D), so as to form a “high-low-high” refractive index layered structure. The coatings (A) and (C) consist of metal oxides, silicate, aluminates and/or a mixture thereof. The coating (B) consist of silicon oxide, hydrous silicon oxide, aluminum oxide, hydrous aluminum oxide, magnesium oxide, hydrous magnesium oxide and/or a mixture thereof. The angle-dependent interference pigments have high color saturation in the transitional region and a significantly gradual color change in the color changing region. The present pigments can be used as colored coatings, including printing ink, or can be used in the preparation of plastics, glass, ceramics and the like. The pigment of the present invention is particularly used in the cosmetic industry which has a very high requirement on gradual color change. | 2011-12-15 |
20110306679 | COMPOSITIONS CONTAINING AGAR AND A SOFTENING AGENT - The present invention includes a composition that has (a) at least one thermo-reversible polysaccharide chosen from agar; (b) at least one softening agent chosen from a cationic surfactant, an anionic surfactant, a nonionic esterified sugar surfactant, a polyorganosiloxane-containing polymer, a sugar silicone surfactant, and mixtures thereof; (c) at least one oil; and (d) water. | 2011-12-15 |
20110306680 | COMPOSITIONS CONTAINING AGAR AND ESTERIFIED SUGAR SURFACTANTS - The present invention is directed to a composition that includes (a) at least one thermo-reversible polysaccharide chosen from agar; (b) at least one softening agent chosen from an esterified sugar surfactant; (c) at least one oil; (d) water; and (e) optionally, at least one emulsifier different from (b), as well as to processes for softening an emulsion containing agar by adding to the emulsion at least one softening agent chosen from an esterified sugar surfactant. | 2011-12-15 |
20110306681 | DEFOAMING METHOD - A defoaming method capable of destroying foams generated when a container is filled with drink, or the like, efficiently at a high speed and destroying foams effectively even in the case of a container having a narrow mouth. Liquid surface ( | 2011-12-15 |
20110306682 | METHOD FOR RECOVERING HYDROCARBON COMPOUNDS AND A HYDROCARBON RECOVERY APPARATUS FROM A GASEOUS BY-PRODUCT - There is provided a method for recovering hydrocarbon compounds from gaseous by-products generated in a Fischer-Tropsch synthesis reaction. The method includes absorbing light hydrocarbon compounds and a carbon dioxide gas from the gaseous by-products using an absorption solvent including liquid hydrocarbon compounds and a carbon dioxide gas absorbent, separating the absorption solvent which has absorbed the light hydrocarbon compounds and the carbon dioxide gas into the liquid hydrocarbon compounds and the carbon dioxide gas absorbent, heating the separated liquid hydrocarbon compounds to recover the light hydrocarbon compounds from the separated liquid hydrocarbon compounds, heating the separated carbon dioxide gas absorbent to strip the carbon dioxide gas from the separated carbon dioxide gas absorbent, and reusing the gaseous by-products from which the light hydrocarbon compounds and the carbon dioxide gas are absorbed as a feedstock gas for the Fischer-Tropsch synthesis reaction. | 2011-12-15 |
20110306683 | FISCHER-TROPSCH CATALYST, PREPARATION METHOD AND APPLICATION THEREOF - A micro-spherical iron-based catalyst and a preparation method thereof are disclosed. The catalyst contains a potassium promoter, and at least one transitional metal promoter M which is one or more kinds of metals selected from Cr, Cu, Mn and Zn. It also contains a structure promoter S, which is SiO | 2011-12-15 |
20110306684 | CHEMICAL PRODUCTION PROCESSES UTILIZING SYNGAS FROM PLASMA PYROLYSIS - Chemical production processes are described herein. The chemical production processes generally include providing municipal solid waste; subjecting the municipal solid waste to plasma pyrolysis to form an intermediate for chemical production, wherein the intermediate includes carbon monoxide and hydrogen; and transferring the intermediate from the plasma pyrolysis to a chemical or liquid fuel production process. | 2011-12-15 |
20110306685 | PROCESS AND SYSTEM FOR REDUCING THE OLEFIN CONTENT OF A FISCHER-TROPSCH PRODUCT STREAM - A method is provided for converting synthesis gas to liquid hydrocarbon mixtures useful as distillate fuel and/or lube base oil containing no greater than about 25 wt % olefins and containing no greater than about 5 wt % C | 2011-12-15 |
20110306686 | ZEOLITE SUPPORTED RUTHENIUM CATALYSTS FOR THE CONVERSION OF SYNTHESIS GAS TO HYDROCARBONS, AND METHOD FOR PREPARATION AND METHOD OF USE THEREOF - A method for forming a catalyst for synthesis gas conversion and a synthesis gas conversion process impregnating a zeolite support wherein the catalyst contains ruthenium on a zeolite support, such as ZSM-5, ZSM-12, SSZ-32 or beta zeolite, and the product stream has less than 1 weight % C | 2011-12-15 |
20110306687 | Polymer compounds and a preparation method thereof - Disclosed herein are polymer compounds and a method for preparing thereof. More specifically, provided are polymer compounds with well-connected, narrow size distribution free-volume element and a method for preparing the polymer compounds by thermal rearrangement for aromatic polyimides containing ortho-positioned functional groups in the solid state. | 2011-12-15 |
20110306688 | METHODS AND SYSTEMS FOR RECYCLING FIBROUS SUBSTRATES - Embodiments of the present disclosure include methods of removing face fibers from a fibrous substrate, systems of removing face fibers from a fibrous substrate, and the like. | 2011-12-15 |
20110306689 | Expandable Polystyrene and Methods of Forming the Same - Expanded polystyrene, foamed articles and methods of making the same are described herein. The expanded polystyrene generally includes polystyrene selected from expandable polystyrene and extrusion polystyrene, the polystyrene exhibiting a molecular weight of from about 130,000 Daltons to about 220,000 Daltons; a melt flow index of from about 20 to about 30 and a density of from about 0.1 lb/ft | 2011-12-15 |
20110306690 | FOAMED POLYESTER EXTRUSION PROCESS AND EQUIPMENT WHICH CAN BE USED IN PLANTS FOR PRODUCING SHEETS, BOARDS OR TUBES OF FOAMED POLYESTER - A foamed polyester extrusion process and equipment can be used in plants for producing sheets, boards or tubes of foamed polyester, preferably of the type operating continuously which has a thermoregulated frame provided with a feeding inlet of pure and/or recycled polyester material inside the frame. Two co-rotating screws are arranged inside the frame, the co-rotating screws defining, with the internal walls of the frame, a first degassing zone interposed between a feeding zone placed at the feeding inlet and a first tight zone. A second degassing zone is placed downstream from the first degassing zone and is separated from the latter through the first tight zone. A foaming agent inlet zone is placed downstream from the second degassing zone and is separated from the latter through a second tight zone and a pumping end zone of the melted material is placed downstream from the foaming agent inlet zone. The first degassing zone has a first vent placed at a first segment of the first degassing zone adjacent to the first tight zone, wherein the first degassing zone is adapted to carry out a forced atmospheric degassing at a temperature lower than the melting point of a treated polyester material, and the second degassing zone is adapted to carry out a vacuum degassing at a temperature equal to or greater than the melting point of the treated polyester material. | 2011-12-15 |